Bausch Health Companies Inc. Stock News

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced comm

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

More coronavirus worries. More misery for these healthcare stocks.

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

Bausch Health Companies (NYSE:BHC) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitabilit

The stock rebounded on Friday in lockstep with the broader biopharmaceutical industry.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * A

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Enz

RAD stock has rallied nicely — and for good reason. While debt remains a key risk, there are positive developments worth highlighting.

Glenview Capital Management’s 13F portfolio value increased from $9.51B to $11.42B this quarter. The number of positions increased from 48 to 50. Larry Robbins

This market has gone to trash incredibly fast, but personally, I don't think people are respecting the downside to this market.

Jeffrey Ubben's 13F portfolio value increased from $9.27B to $9.88B this quarter. ValueAct added FedEx and Verra Mobility while decreasing Alliance Data Systems